-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-05-05
UNC:F:F-UCB SA (EUR)
COMMON STOCK | Biotechnology |
Last Closing
USD 120.6Change
0.00 (0.00)%Market Cap
USD 22.90BVolume
78.00Analyst Target
N/AVerdict
Verdict
Values as of: 2024-05-05
COMMON STOCK | Biotechnology |
Last Closing
USD 120.6Change
0.00 (0.00)%Market Cap
USD 22.90BVolume
78.00Analyst Target
N/AVerdict
Verdict
Currency: EUR
Country : Germany
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
NOVA:F | Novo Nordisk A/S |
N/A |
USD 519.71B |
VX1:F | Vertex Pharmaceuticals Incorpo.. |
N/A |
USD 101.21B |
RGO:F | Regeneron Pharmaceuticals Inc |
N/A |
USD 100.87B |
CSJA:F | CSL LTD SPON.ADR 2 |
N/A |
USD 81.84B |
CSJ:F | CSL Limited |
N/A |
USD 81.66B |
0QF:F | Moderna Inc |
N/A |
USD 46.87B |
UNC0:F | UCB S.A. UNSP.ADR 1/2 |
N/A |
USD 23.11B |
22UA:F | BioNTech SE |
N/A |
USD 20.71B |
1AE:F | Argen-X |
N/A |
USD 20.49B |
1AEA:F | argenx SE |
N/A |
USD 20.33B |
N/A
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 53.44% | 87% | B+ | 95% | A | ||
Dividend Return | 1.73% | 64% | D | 47% | F | ||
Total Return | 55.17% | 87% | B+ | 91% | A- | ||
Trailing 12 Months | |||||||
Capital Gain | 47.18% | 83% | B | 87% | B+ | ||
Dividend Return | 1.66% | 29% | F | 16% | F | ||
Total Return | 48.84% | 83% | B | 81% | B- | ||
Trailing 5 Years | |||||||
Capital Gain | 76.01% | 76% | C+ | 81% | B- | ||
Dividend Return | 5.74% | 44% | F | 22% | F | ||
Total Return | 81.74% | 75% | C | 70% | C- | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 6.25% | 77% | C+ | 68% | D+ | ||
Dividend Return | 7.10% | 77% | C+ | 64% | D | ||
Total Return | 0.85% | 74% | C | 30% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 23.02% | 66% | D+ | 51% | F | ||
Risk Adjusted Return | 30.84% | 81% | B- | 62% | D | ||
Market Capitalization | 22.90B | 99% | N/A | 93% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector